FDA approves Roche’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss January 31, 2022February 22, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: FDA approves Roche’s Vabysmo, the first bispecific…European Commission approves Roche’s Vabysmo, the…CHMP recommends EU approval of Roche’s Vabysmo, the…New two-year data for Roche’s Vabysmo and Susvimo…New two-year data for Roche’s Vabysmo and Susvimo…The Lancet publishes studies showing Roche’s…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
